EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links


[Gastric cancer 829. ESD for gastric tube cancer]

Previous | Next

001 | 101 | 201 | 301 | 401 | 501 | 601 | 701 | 801 | 901 | 1000


13 years after Ivor Lewis operation and chemotherapy for upper esophageal cancer (squamous cell carcinoma, pT3N1), gastric tube cancer was found at 37 cm from the incisor teeths. Biopsy showed tubular adenocarcinoma, moderately differentiated with focal poorly differentiated component.

Based on the endoscopic findings (depressed lesion, converging folds) and histologic findings, I recommended surgery. However, the surgeon recommended performing ESD due to the high surgical risk. ESD was done.


ESD: Early gastric carcinoma
1. Location : Intrathoracic stomach, IT 37cm
2. Gross type : EGC type IIa+IIb
3. Histologic type : tubular adenocarcinoma, moderately differentiated, >> tubular adenocarcinoma, poorly differentiated (poorly cohesive)
4. Histologic type by Lauren : mixed
5. Size of carcinoma : (1) longest diameter,14 mm (2) vertical diameter, 18 mm
6. Depth of invasion : invades submucosa, (depth of sm invasion : 2000 §­) (pT1b)
7. Resection margin : involved deep resection margin by carcinoma, safety margin : distal 4 mm, proximal 1 mm, anterior 4 mm, posterior 2 mm, deep 0 §­
8. Lymphatic invasion : present (+++)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: present

Based on the pathology, surgery is necessary. The problem is the surgical risk. Surgical consultation was done. I explained the situation to the patient in detail.

¾î´À Á¤µµ ¿ì·ÁÇÑ ¹Ù¿´Áö¸¸ ¾Æ½¬¿î °á°ú¿´½À´Ï´Ù.

ºñ±³Àû ÀÛÀº Á¶±âÀ§¾ÏÀÌÁö¸¸ ÇÔ¸ôÇüÀÌ°í Á¶Á÷°Ë»ç¿¡¼­ ¹ÌºÐÈ­ ¿ä¼Ò°¡ ÀÖ´Â °ÍÀ¸·Î ³ª¿Í ¼ö¼úÀû Ä¡·á°¡ ÇÊ¿äÇÑ »óȲÀ̾ú½À´Ï´Ù. ±×·¯³ª ½Äµµ¾Ï ¼ö¼úÀ» ¹ÞÀ¸½Å ºÐÀÌ°í °Ô´Ù°¡ ÀÎÈÄºÎ¾Ï ¹æ»ç¼± Ä¡·á ÇϽŠºÐÀ̽ùǷΠÀ§ ¼ö¼úÀ» ÇÏ¸é ½Äµµ¿Í ÀåÀ» ¿¬°áÇØ¾ß Çϴµ¥ ½ÄµµÀÇ ´ëºÎºÐÀÌ ¾ø¾î¼­ ¸Å¿ì À§ÇèÇÏ°í Å« ¼ö¼úÀÌ µÉ ¼ö ¹Û¿¡ ¾ø´Â »óȲÀÎ °Íµµ »ç½ÇÀ̾ú½À´Ï´Ù. µû¶ó¼­ ¼ö¼ú¿¡ µû¸¥ À§Ç輺ÀÌ ¸Å¿ì ³ô¾Æ¼­ Àß »óÀÇÇÏ¿© Ä¡·á¹ýÀ» ¼±ÅÃÇÏ´Â ¼ö ¹Û¿¡ ¾ø´Ù°í ¼³¸íµå·È½À´Ï´Ù. µû¶ó¼­ ÁÖ Áø·á°úÀÎ ÈäºÎ¿Ü°ú¿Í »óÀǸ¦ ÇÏ¿´°í ÀÏ´Ü ³»½Ã°æ Ä¡·á (ESD)¸¦ ÇØ º¼ °ÍÀ» ±ÇÀ¯¹Þ¾Æ ½Ã¼úÀ» ¹Þ¾Ò½À´Ï´Ù. À§¾ÏÀ̱â´Â ÇÏÁö¸¸ À§Ä¡°¡ Èä°­³»¿´±â ¶§¹®¿¡ »ó´çÈ÷ °í³­À̵µ ½Ã¼úÀ̾ú½À´Ï´Ù¸¸ ´ÙÇེ·´°Ô ³»½Ã°æ ½Ã¼úÀº Àß µÇ¾ú½À´Ï´Ù. ±×·±µ¥ ³»½Ã°æÀ¸·Î ÀýÁ¦ÇÑ Ç¥º»¿¡ ´ëÇÑ ÃÖÁ¾ º´¸®°á°ú¿¡¼­ ¼¼Æ÷Çü, ±íÀÌ, ¹üÀ§, ¸²ÇÁ°ü/Ç÷°ü¿¡ ¸ðµÎ ¹®Á¦°¡ ¾ø¾î¾ß Çϴµ¥ ¾Æ½±°Ôµµ ¹®Á¦°¡ »ó´çÈ÷ ÀÖ´Â °ÍÀ¸·Î ³ª¿Ô½À´Ï´Ù. (1) Á¶Á÷Çü¿¡¼­ ¹ÌºÐÈ­ ¿ä¼Ò°¡ ¼¯¿© ÀÖ°í (»çÀü¿¡ ¾Ë°í ÀÖ´ø ¹ÙÀÓ) (2) Á¦2ÃþÀÎ Á¡¸·ÇÏÃþ¿¡ ±í°Ô ħÀ±µÇ¾î ÀÖ°í, (3) ÀýÁ¦º¯¿¬ ¾ç¼ºÀÌ°í, (4) Á¾¾çÀÌ ¸²ÇÁ°ü ħÀ±ÀÌ ¶Ñ·ÈÇÏ¿´½À´Ï´Ù. Áï ¼ö¼úÀÌ ÇÊ¿äÇÑ °ÍÀ¸·Î ³ª¿Ô½À´Ï´Ù.

º´¸®°á°ú¿¡ ¹®Á¦°¡ ¾øÀ» ¶§ Àç¹ß·üÀÌ 5% Á¤µµÀε¥ ¹ÝÇÏ¿©, ÇöÀçÀÇ Àç¹ß À§ÇèÀº ÈξÀ ÈξÀ ´õ ³ô½À´Ï´Ù. Àç¹ßÇÏ¸é ¿ÏÄ¡ÀÇ ±âȸ´Â ÈçÄ¡ ¾Ê½À´Ï´Ù. µû¶ó¼­ ¼ö¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¹®Á¦´Â ¼ö¼ú¿¡ µû¸¥ À§Ç輺ÀÔ´Ï´Ù. ÀϹÝÀûÀÎ ºÐµé°ú ¸¶Âù°¡Áö·Î Àü½Å¸¶Ãë¿¡ µû¸¥ À§Çè, ÅëÁõ, ¼ö¼úÀÇ ÇÕº´Áõ, ¼ö¼ú ÈÄ »îÀÇ Áú ÀúÇÏ µîÀÇ ¾î·Á¿î Á¡ »Ó¸¸ ¾Æ´Ï¶ó °ú°Å ½Äµµ¾ÏÀ¸·Î ¼ö¼úÇÏ¿© ´ëºÎºÐÀÇ ½Äµµ¸¦ Á¦°ÅÇÏ¿´°í Èä°­ ³»¿¡ À§Ä¡ÇÑ À§¿¡¼­ ¾ÏÀÌ ¹ß»ýÇÏ¿´±â ¶§¹®¿¡ ¼ö¼ú¿¡ µû¸¥ À§Ç輺Àº ¸Å¿ì ³ô½À´Ï´Ù. ÇöÀç ¾ÏÀÌ ³²¾ÆÀÖ´Ù´Â Áõ°Å°¡ ÀÖ¾î ¼ö¼úÀ» ±ÇÇÏ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ÀÏ´Ü ³»½Ã°æÀ¸·Î´Â º¸ÀÌ´Â ¾ÏÀº Á¦°ÅÇß½À´Ï´Ù. ´ÜÁö º´¸® °á°ú¿¡¼­ Àç¹ßÀ§ÇèÀÌ ¾ÆÁÖ ¸¹ÀÌ ³ô´Ù°í ³ª¿Ô±â ¶§¹®¿¡ ¼ö¼úÀ» ±ÇÇÏ´Â °ÍÀÔ´Ï´Ù. ¼ö¼úÀ» Çغ¸¸é ´«¿¡ º¸ÀÏ Á¤µµÀÇ ¾ÏÀÌ ³²¾ÆÀÖ´Â °æ¿ìµµ ÀÖ°í ±×·¸Áö ¾ÊÀº °æ¿ìµµ ÀÖ½À´Ï´Ù. ÀÏ´Ü ¼ö¼úÀ» ±ÇÇÒ ¼ö ¹Û¿¡ ¾ø´Â »óȲÀÌ°í ¼ö¼úÀÇ À§Ç輺À» °í·ÁÇÑ Ãß°¡ ÆÇ´ÜÀº ÈäºÎ¿Ü°ú¿¡ ÀÇ·ÚÇÒ ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù.

°èȹ: ÈäºÎ ¿Ü°ú ÀÇ·Ú (½Äµµ¾Ï ¼ö¼ú ÈÄ intrathoracic gastric cancer¿¡ ´ëÇÑ ESD¸¦ ½ÃÇàÇÏ¿´À¸³ª ÃÖÁ¾ º´¸® °á°ú deep SM invasion, vertical margin positive, lymphatic invasion (+++) ¼Ò°ßÀ¸·Î ³ª¿Í ¼ö¼úÀû Ä¡·á¸¦ À§ÇÏ¿© ÀǷڵ帳´Ï´Ù. ¼ö¼ú À§Ç輺ÀÌ ¸Å¿ì ³ôÀº ºÐÀ̹ǷΠ±Í°úÀû »ó´ãÀ» ºÎŹµå¸³´Ï´Ù.)



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (2020-2-11)